Investigational New Drugs

, Volume 29, Issue 2, pp 366–373 | Cite as

A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer

  • Chul Kim
  • Jae-Lyun Lee
  • Min-Hee Ryu
  • Heung Moon Chang
  • Tae Won Kim
  • Ho Young Lim
  • Hye Jin Kang
  • Young Suk Park
  • Baek-Yeol Ryoo
  • Yoon-Koo Kang


Background We evaluated the efficacy and safety of cetuximab in combination with XELOX [XELoda® (capecitabine) and OXaliplatin] in advanced gastric cancer (AGC) patients. The objectives were to evaluate overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety of cetuximab plus XELOX. Methods Previously untreated AGC patients received intravenous infusion of cetuximab 400 mg/m2 on day 1 followed by weekly infusions of 250 mg/m2. Oxaliplatin 130 mg/m2 was administered intravenously on day 1 and capecitabine 1,000 mg/m2 bid was administered orally for 14 days of a 3-week cycle. Chemotherapy was given until disease progression or intolerable toxicities. On completing maximum 8 cycles of chemotherapy, patients were allowed weekly cetuximab until progression. Response evaluations were done every two cycles and toxicities were assessed at each visit. Results Forty-four patients (29 male) were enrolled; median age was 57.5 years (range 36-70). In total, 253 cycles of XELOX chemotherapy (range 1–8, median 6.5 cycles) and 917 cetuximab infusions (range 1–58, median 19.0) were delivered. Overall RR was 52.3%. Median PFS and OS were 6.5 months (95% CI, 4.9–8.4) and 11.8 months (95% CI, 6.7–16.8), respectively. The most common toxicities of all grades were anemia (81.8% of patients), asthenia (81.8%), anorexia (79.6%), hand-foot syndrome (79.6%), acneiform skin eruption (77.2%), and sensory neuropathy (75.0%), and they were mostly grade 1 or 2. Grade 3–4 hematologic toxicities were uncommon (anemia, 6.8%; thrombocytopenia, 2.3%). Conclusions Cetuximab in combination with XELOX chemotherapy was active and safe as first-line treatment of metastatic and/or recurrent AGC patients.


Cetuximab Targeted therapy Capecitabine Oxaliplatin Gastric cancer 



Potential conflict of interest: Dr. Yoon-Koo Kang received honoraria for lecture from Merck, Roche, and Sanofi-Aventis.

Study drugs (cetuximab, capecitabine, and oxaliplatin) were supported by Merck, Roche, and Sanofi-Aventis


  1. 1.
    Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578CrossRefPubMedGoogle Scholar
  2. 2.
    Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA (2005) Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23:8646–8654CrossRefPubMedGoogle Scholar
  3. 3.
    Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A et al (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803–1810CrossRefPubMedGoogle Scholar
  4. 4.
    Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345CrossRefPubMedGoogle Scholar
  5. 5.
    Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36–46CrossRefPubMedGoogle Scholar
  6. 6.
    De Jong KP, Stellema R, Karrenbeld A, Koudstaal J, Gouw AS, Sluiter WJ et al (1998) Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology 28:971–979CrossRefPubMedGoogle Scholar
  7. 7.
    Folprecht G, Lutz MP, Schoffski P, Seufferlein T, Nolting A, Pollert P et al (2006) Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17:450–456CrossRefPubMedGoogle Scholar
  8. 8.
    Garcia I, Vizoso F, Martin A, Sanz L, Abdel-Lah O, Raigoso P et al (2003) Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 10:234–241CrossRefPubMedGoogle Scholar
  9. 9.
    Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U et al (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163–168CrossRefPubMedGoogle Scholar
  10. 10.
    Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS et al (2009) Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 100:298–304CrossRefPubMedGoogle Scholar
  11. 11.
    Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N et al (2005) Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23:5578–5587CrossRefPubMedGoogle Scholar
  12. 12.
    Hong YS, Song SY, Lee SI, Chung HC, Choi SH, Noh SH et al (2004) A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol 15:1344–1347CrossRefPubMedGoogle Scholar
  13. 13.
    Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040–2048CrossRefPubMedGoogle Scholar
  14. 14.
    Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J et al (2009) Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 20:666–673CrossRefPubMedGoogle Scholar
  15. 15.
    Kim TW, Kang YK, Ahn JH, Chang HM, Yook JH, Oh ST et al (2002) Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol 13:1893–1898CrossRefPubMedGoogle Scholar
  16. 16.
    Kopp R, Ruge M, Rothbauer E, Cramer C, Kraemling HJ, Wiebeck B et al (2002) Impact of epidermal growth factor (EGF) radioreceptor analysis on long-term survival of gastric cancer patients. Anticancer Res 22:1161–1167PubMedGoogle Scholar
  17. 17.
    Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M et al (2008) Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 15:69–79CrossRefPubMedGoogle Scholar
  18. 18.
    Lordick FLS, Hegewisch-Becker S, Folprecht G, Wöll E, Decker T, Endlicher E et al (2007) Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group. J Clin Oncol 4526Google Scholar
  19. 19.
    Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K et al (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274–1281CrossRefPubMedGoogle Scholar
  20. 20.
    Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37–41CrossRefPubMedGoogle Scholar
  21. 21.
    Park YH, Lee JL, Ryoo BY, Ryu MH, Yang SH, Kim BS et al (2008) Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer. Cancer Chemother Pharmacol 61:623–629CrossRefPubMedGoogle Scholar
  22. 22.
    Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108CrossRefPubMedGoogle Scholar
  23. 23.
    Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C et al (2007) Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 18:510–517CrossRefPubMedGoogle Scholar
  24. 24.
    Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587–591CrossRefPubMedGoogle Scholar
  25. 25.
    Raymond E, Faivre S, Armand JP (2000) Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 60(Suppl 1):15–23 discussion 41–2CrossRefPubMedGoogle Scholar
  26. 26.
    Sakamoto J, Chin K, Kondo K, Kojima H, Terashima M, Yamamura Y et al (2006) Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer. Anticancer Drugs 17:231–236CrossRefPubMedGoogle Scholar
  27. 27.
    Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201–1208CrossRefPubMedGoogle Scholar
  28. 28.
    Slesak B, Harlozinska A, Porebska I, Bojarowski T, Lapinska J, Rzeszutko M et al (1998) Expression of epidermal growth factor receptor family proteins (EGFR, c-erbB-2 and c-erbB-3) in gastric cancer and chronic gastritis. Anticancer Res 18:2727–2732PubMedGoogle Scholar
  29. 29.
    Tabernero J, Macarulla T, Ramos FJ, Baselga J (2005) Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol 16:1740–1748CrossRefPubMedGoogle Scholar
  30. 30.
    Tokunaga A, Onda M, Okuda T, Teramoto T, Fujita I, Mizutani T et al (1995) Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer 75:1418–1425CrossRefPubMedGoogle Scholar
  31. 31.
    Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991–4997CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Chul Kim
    • 1
  • Jae-Lyun Lee
    • 1
  • Min-Hee Ryu
    • 1
  • Heung Moon Chang
    • 1
  • Tae Won Kim
    • 1
  • Ho Young Lim
    • 2
  • Hye Jin Kang
    • 3
  • Young Suk Park
    • 2
  • Baek-Yeol Ryoo
    • 1
  • Yoon-Koo Kang
    • 1
  1. 1.Department of OncologyAsan Medical Center, University of Ulsan College of MedicineSeoulSouth Korea
  2. 2.Division of Hematology-Oncology, Department of Medicine, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulKorea
  3. 3.Division of Hematology and Oncology, Department of Internal MedicineKorea Institute of Radiological and Medical SciencesSeoulSouth Korea

Personalised recommendations